Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

MIRA Pharmaceuticals, Inc.

$0.95

-0.03 (-2.64%)

Market Cap
41.69 M
EPS
-1.44
P/E Ratio
-
Value Trade
99.28 K
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • R&D Expenses

    524.78 K

  • Operating CF

    -1.20 M

  • Total Assets

    9.46 M

  • Total Liabilities

    114.76 K

  • Equity

    9.35 M

  • D/E Ratio

    12,345

3.01 %
Week
-10.63 %
1 Month
-16.64 %
3 Month
-25.41 %
6 Month
-85.83 %
5 Year
-85.83 %
All Time
Cash Data
Stable

  • Cash Position

    9.41 M

  • Monthly Burn

    400.00 K

  • Runway

    22.4 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 14, 2026
Overview
Volume
69.67 K
52 Week Range
0.90 - 2.45
% held by Insiders
16.53 %
% held by Institutions
5.11 %
Enterprise Value
32.28 M
Total Shares
42.00 M
Short %
1.26 %
Float Shares
29.19 M
Company Description
HQ: 1200 BRICKELL AVENUE, MIAMI, F...
Employees:2
https://www.mirapharmaceutical...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Ketamir-2
neuropathic pain
Phase 1
2025-07-30

In a chemotherapy-induced neuropathy model, Ketamir-2 achieved near-complete normalization of pain sensitivity and outperformed gabapentin by 60%,In a validated diabetic neuropathy model induced by a high-fat diet and low-dose streptozotocin (STZ) in rats, Ketamir-2 significantly reduced pain sensitivity, with some animals returning to pre-diabetic baseline sensitivity,In head-to-head studies using the chronic constriction injury (CCI) model, Ketamir-2 delivered up to 112% greater pain relief than pregabalin and 70% more than gabapentin,No hyperlocomotion, sedation, or behavioral disturbances were observed, even at high doses,A comprehensive neurotoxicity study confirmed absence of Olney lesions, a key safety concern in NMDA modulators like ketamine,Ketamir-2 was shown to cross the blood-brain barrier efficiently, supported by its non-P-gp substrate status and evidence of CNS penetration in preclinical models,Preclinical data indicate Ketamir-2 achieves good oral bioavailability-significantly higher than traditional ketamine

Ketamir-2
neuropathic pain
Phase 1
2025-07-30

In a chemotherapy-induced neuropathy model, Ketamir-2 achieved near-complete normalization of pain sensitivity and outperformed gabapentin by 60%,In a validated diabetic neuropathy model induced by a high-fat diet and low-dose streptozotocin (STZ) in rats, Ketamir-2 significantly reduced pain sensitivity, with some animals returning to pre-diabetic baseline sensitivity,In head-to-head studies using the chronic constriction injury (CCI) model, Ketamir-2 delivered up to 112% greater pain relief than pregabalin and 70% more than gabapentin,No hyperlocomotion, sedation, or behavioral disturbances were observed, even at high doses,A comprehensive neurotoxicity study confirmed absence of Olney lesions, a key safety concern in NMDA modulators like ketamine,Ketamir-2 was shown to cross the blood-brain barrier efficiently, supported by its non-P-gp substrate status and evidence of CNS penetration in preclinical models,Preclinical data indicate Ketamir-2 achieves good oral bioavailability-significantly higher than traditional ketamine

Ketamir-2
neuropathic pain
Phase 1
2025-07-30

In a chemotherapy-induced neuropathy model, Ketamir-2 achieved near-complete normalization of pain sensitivity and outperformed gabapentin by 60%,In a validated diabetic neuropathy model induced by a high-fat diet and low-dose streptozotocin (STZ) in rats, Ketamir-2 significantly reduced pain sensitivity, with some animals returning to pre-diabetic baseline sensitivity,In head-to-head studies using the chronic constriction injury (CCI) model, Ketamir-2 delivered up to 112% greater pain relief than pregabalin and 70% more than gabapentin,No hyperlocomotion, sedation, or behavioral disturbances were observed, even at high doses,A comprehensive neurotoxicity study confirmed absence of Olney lesions, a key safety concern in NMDA modulators like ketamine,Ketamir-2 was shown to cross the blood-brain barrier efficiently, supported by its non-P-gp substrate status and evidence of CNS penetration in preclinical models,Preclinical data indicate Ketamir-2 achieves good oral bioavailability-significantly higher than traditional ketamine

Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in MIRA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
MIRA Pharmaceuticals, Inc. (MIRA) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
MIRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MIRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MIRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
MIRA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
MIRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MIRA
Mar 4, 2026
MIRAPhases

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

MIRA Pharmaceuticals has completed Phase 1 dosing of Ketamir-2, a selective oral NMDA receptor modulator, with favorable safety and tolerability outcomes. The study involved 56 healthy volunteers, and no serious adverse events were reported. MIRA plans to submit documentation for a Phase 2a trial targeting chemotherapy-induced peripheral neuropathy, a condition lacking FDA-approved therapies.

Read more →
MIRA
Feb 3, 2026
MIRAPhases

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

MIRA Pharmaceuticals has commenced dosing in the final cohort of its Phase 1 clinical trial for Ketamir-2, an oral NMDA receptor antagonist. The trial aims to evaluate the safety and pharmacokinetics of the drug, with no serious adverse events reported thus far. MIRA plans to submit a Phase 2a protocol to the FDA following the completion of Phase 1, targeting chemotherapy-induced peripheral neuropathy, a condition with no approved treatments.

Read more →
Competitive Position
How MIRA ranks across every disease it competes in
Competitive Position is a premium feature
See how MIRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial